Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 2/20 | 0.41 |
| ▸ | ATP4B | P51164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.40 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RHOA | P61586 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14224941 | 0.88 | SCD (0.47) | ATP4AATP4BALDH1A1NPC1PKM | |
| SCHEMBL16404111 | 0.77 | ATP4A (0.46) | ATP4AATP4BALDH1A1NPC1PKM | |
| SCHEMBL14325803 | 0.75 | ROCK2 (0.44) | ATP4AATP4BALDH1A1NPC1PKM | |
| SCHEMBL16404065 | 0.75 | ATP4A (0.64) | ATP4AATP4BALDH1A1NPC1PKM | |
| SCHEMBL14318291 | 0.75 | ATP4A (0.67) | ATP4AATP4BALDH1A1NPC1PKM | |
| SCHEMBL16404152 | 0.74 | ATP4A (0.54) | ATP4AATP4BALDH1A1NPC1PKM | |
| SCHEMBL16404112 | 0.74 | ATP4A (0.53) | ATP4AATP4BALDH1A1NPC1PKM | |
| SCHEMBL14318276 | 0.74 | ATP4A (0.69) | ATP4AATP4BALDH1A1NPC1PKM | |
| SCHEMBL16404143 | 0.73 | ATP4A (0.53) | ATP4AATP4BALDH1A1NPC1PKM | |
| SCHEMBL16404141 | 0.72 | ATP4A (0.52) | ATP4AATP4BALDH1A1NPC1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937065-B2 | Compositions and methods for modulating a kinase | CLEVEXEL PHARMA (FR) | 2015-01-20 | — | — | US | disclosed |
| US-8937065-B2 | Compositions and methods for modulating a kinase | CLEVEXEL PHARMA (FR) | 2015-01-20 | — | — | US | disclosed |
| WO-2012172438-A9 | COMPOSITIONS AND METHODS FOR MODULATING A KINASE | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2013-02-07 | — | — | WO | disclosed |
| WO-2012172438-A2 | COMPOSITIONS AND METHODS FOR MODULATING A KINASE | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-12-20 | — | — | WO | disclosed |
| US-20120316148-A1 | Compositions and Methods for Modulating a Kinase | DYNAMIX PHARMACEUTICALS LTD. (IL) | 2012-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316148-A1 | Compositions and Methods for Modulating a Kinase | PRKCH, MAP3K2, MAP3K6 | ATP4A 4242/4885ATP4B 4379/4885ALDH1A1 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.